TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

PURPOSE: Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. PATIENTS AND METHODS: In this randomized phase II trial,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carey, Lisa A., Rugo, Hope S., Marcom, P. Kelly, Mayer, Erica L., Esteva, Francisco J., Ma, Cynthia X., Liu, Minetta C., Storniolo, Anna Maria, Rimawi, Mothaffar F., Forero-Torres, Andres, Wolff, Antonio C., Hobday, Timothy J., Ivanova, Anastasia, Chiu, Wing-Keung, Ferraro, Madlyn, Burrows, Emily, Bernard, Philip S., Hoadley, Katherine A., Perou, Charles M., Winer, Eric P.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2012
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3413275/
https://ncbi.nlm.nih.gov/pubmed/22665533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.5579
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares